CRSP
Price
$42.27
Change
+$0.23 (+0.55%)
Updated
Jan 31, 10:41 AM (EDT)
Capitalization
3.52B
18 days until earnings call
CRVS
Price
$5.42
Change
+$0.13 (+2.46%)
Updated
Jan 31, 10:41 AM (EDT)
Capitalization
326.43M
34 days until earnings call
Ad is loading...

CRSP vs CRVS

Header iconCRSP vs CRVS Comparison
Open Charts CRSP vs CRVSBanner chart's image
CRISPR Therapeutics AG
Price$42.27
Change+$0.23 (+0.55%)
Volume$4.04K
Capitalization3.52B
Corvus Pharmaceuticals
Price$5.42
Change+$0.13 (+2.46%)
Volume$300
Capitalization326.43M
CRSP vs CRVS Comparison Chart
Loading...
CRSP
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
CRVS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
CRSP vs. CRVS commentary
Jan 31, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CRSP is a StrongBuy and CRVS is a StrongBuy.

Ad is loading...
COMPARISON
Comparison
Jan 31, 2025
Stock price -- (CRSP: $42.04 vs. CRVS: $5.29)
Brand notoriety: CRSP and CRVS are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CRSP: 86% vs. CRVS: 37%
Market capitalization -- CRSP: $3.52B vs. CRVS: $326.43M
CRSP [@Biotechnology] is valued at $3.52B. CRVS’s [@Biotechnology] market capitalization is $326.43M. The market cap for tickers in the [@Biotechnology] industry ranges from $379.55B to $0. The average market capitalization across the [@Biotechnology] industry is $2.47B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CRSP’s FA Score shows that 0 FA rating(s) are green whileCRVS’s FA Score has 0 green FA rating(s).

  • CRSP’s FA Score: 0 green, 5 red.
  • CRVS’s FA Score: 0 green, 5 red.
According to our system of comparison, CRVS is a better buy in the long-term than CRSP.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CRSP’s TA Score shows that 3 TA indicator(s) are bullish while CRVS’s TA Score has 3 bullish TA indicator(s).

  • CRSP’s TA Score: 3 bullish, 4 bearish.
  • CRVS’s TA Score: 3 bullish, 2 bearish.
According to our system of comparison, CRVS is a better buy in the short-term than CRSP.

Price Growth

CRSP (@Biotechnology) experienced а -4.95% price change this week, while CRVS (@Biotechnology) price change was -0.19% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -1.11%. For the same industry, the average monthly price growth was +1.05%, and the average quarterly price growth was +4.49%.

Reported Earning Dates

CRSP is expected to report earnings on May 12, 2025.

CRVS is expected to report earnings on May 12, 2025.

Industries' Descriptions

@Biotechnology (-1.11% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
CRSP($3.52B) has a higher market cap than CRVS($326M). CRSP YTD gains are higher at: 6.809 vs. CRVS (-1.121). CRVS has higher annual earnings (EBITDA): -25M vs. CRSP (-313.08M). CRSP has more cash in the bank: 1.94B vs. CRVS (41.7M). CRVS has less debt than CRSP: CRVS (354K) vs CRSP (228M). CRSP has higher revenues than CRVS: CRSP (200M) vs CRVS (0).
CRSPCRVSCRSP / CRVS
Capitalization3.52B326M1,079%
EBITDA-313.08M-25M1,252%
Gain YTD6.809-1.121-607%
P/E RatioN/AN/A-
Revenue200M0-
Total Cash1.94B41.7M4,643%
Total Debt228M354K64,407%
FUNDAMENTALS RATINGS
CRSP vs CRVS: Fundamental Ratings
CRSP
CRVS
OUTLOOK RATING
1..100
1268
VALUATION
overvalued / fair valued / undervalued
1..100
62
Fair valued
83
Overvalued
PROFIT vs RISK RATING
1..100
10085
SMR RATING
1..100
9399
PRICE GROWTH RATING
1..100
6240
P/E GROWTH RATING
1..100
8398
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

CRSP's Valuation (62) in the Biotechnology industry is in the same range as CRVS (83) in the Pharmaceuticals Major industry. This means that CRSP’s stock grew similarly to CRVS’s over the last 12 months.

CRVS's Profit vs Risk Rating (85) in the Pharmaceuticals Major industry is in the same range as CRSP (100) in the Biotechnology industry. This means that CRVS’s stock grew similarly to CRSP’s over the last 12 months.

CRSP's SMR Rating (93) in the Biotechnology industry is in the same range as CRVS (99) in the Pharmaceuticals Major industry. This means that CRSP’s stock grew similarly to CRVS’s over the last 12 months.

CRVS's Price Growth Rating (40) in the Pharmaceuticals Major industry is in the same range as CRSP (62) in the Biotechnology industry. This means that CRVS’s stock grew similarly to CRSP’s over the last 12 months.

CRSP's P/E Growth Rating (83) in the Biotechnology industry is in the same range as CRVS (98) in the Pharmaceuticals Major industry. This means that CRSP’s stock grew similarly to CRVS’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CRSPCRVS
RSI
ODDS (%)
N/A
N/A
Stochastic
ODDS (%)
Bearish Trend 3 days ago
84%
Bullish Trend 3 days ago
82%
Momentum
ODDS (%)
Bullish Trend 3 days ago
79%
Bearish Trend 3 days ago
86%
MACD
ODDS (%)
Bullish Trend 3 days ago
77%
Bullish Trend 3 days ago
90%
TrendWeek
ODDS (%)
Bearish Trend 3 days ago
82%
Bearish Trend 3 days ago
89%
TrendMonth
ODDS (%)
Bullish Trend 3 days ago
79%
Bullish Trend 3 days ago
85%
Advances
ODDS (%)
Bullish Trend 30 days ago
81%
Bullish Trend 26 days ago
80%
Declines
ODDS (%)
Bearish Trend 3 days ago
84%
Bearish Trend 5 days ago
90%
BollingerBands
ODDS (%)
Bearish Trend 3 days ago
90%
N/A
Aroon
ODDS (%)
Bearish Trend 3 days ago
83%
N/A
View a ticker or compare two or three
Ad is loading...
CRSP
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
CRVS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
PESPX29.590.34
+1.16%
BNY Mellon MidCap Index Inv
ALABX12.560.01
+0.08%
ALPS/Smith Balanced Opportunity A
WHGIX12.24N/A
N/A
Westwood Income Opportunity Instl
FRUAX22.60N/A
N/A
Franklin Utilities Adv
ETLNX14.35N/A
N/A
Eventide Large Cap Focus N

CRSP and

Correlation & Price change

A.I.dvisor indicates that over the last year, CRSP has been closely correlated with BEAM. These tickers have moved in lockstep 71% of the time. This A.I.-generated data suggests there is a high statistical probability that if CRSP jumps, then BEAM could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CRSP
1D Price
Change %
CRSP100%
+2.01%
BEAM - CRSP
71%
Closely correlated
+5.29%
PRME - CRSP
64%
Loosely correlated
+2.91%
RXRX - CRSP
64%
Loosely correlated
+7.40%
NTLA - CRSP
62%
Loosely correlated
+3.85%
EDIT - CRSP
59%
Loosely correlated
+2.24%
More

CRVS and

Correlation & Price change

A.I.dvisor indicates that over the last year, CRVS has been loosely correlated with FULC. These tickers have moved in lockstep 34% of the time. This A.I.-generated data suggests there is some statistical probability that if CRVS jumps, then FULC could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CRVS
1D Price
Change %
CRVS100%
+4.13%
FULC - CRVS
34%
Loosely correlated
+2.45%
VCYT - CRVS
33%
Poorly correlated
+3.83%
VRDN - CRVS
33%
Poorly correlated
+3.35%
KROS - CRVS
32%
Poorly correlated
+2.99%
CRSP - CRVS
32%
Poorly correlated
+2.01%
More